TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04254627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 300 mg pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 300 mg pill
Study: NCT06567847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Enriched Exercise
Description: An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise
Description: Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
Study: NCT04629196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: A second IV weight-based induction dose of Stelara at week 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: A standard 90mg subcutaneous dose of Stelara at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
Study: NCT05676320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Flex
Description: Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Steady
Description: Bone Cement alone
Study: NCT05999474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tioconazole
Description: Laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tioconazole
Description: Laser
Study: NCT04852588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)
Description: Chest lymph node sampling procedure by EBUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
Description: Chest lymph node sampling procedure by EUS
Study: NCT05785117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Stimulation
Description: ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training program
Description: The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training program
Description: The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
Study: NCT05837676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Training for Concussion
Description: PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
Study: NCT06555029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR Changes
Description: Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training
Description: Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADA Oral Health Training
Description: Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter.
Study: NCT05506930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
Study: NCT04753463

Intervention type: OTHER
Intervention: Survey
Description: The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
Study: NCT04158635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Given PO
Study: NCT05113927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selene
Description: SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
Study: NCT05037851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opelconazole
Description: Nebulizer suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT05933122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexologist consult
Description: in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standart of care
Description: in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist
Study: NCT05621798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Manufacturer's Software
Description: When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Manufacturer's Software
Description: When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REM (Real Ear Measurements)
Description: Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REM (Real Ear Measurements)
Description: Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
Study: NCT06364150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell injection
Description: For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
Study: NCT05869643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule, taken orally once daily after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule, taken orally once daily after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule, taken orally once daily after breakfast
Study: NCT06478680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exoskeleton mediated gait training
Description: 1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity gait training
Description: 2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement
Study: NCT05581160

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Description: Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C.
Study: NCT04158635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Given PO
Study: NCT05604391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft placed apically
Description: For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft placed coronally
Description: For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
Study: NCT04478305

Intervention type: DRUG
Group type: OTHER
Intervention: Duavive 0.45Mg-20Mg Tablet
Description: Duavee, marketed as Duavive in Canada.
Study: NCT05560399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for
Study: NCT06468657

Intervention type: OTHER
Intervention: mortality rates
Description: mortality rates

Intervention type: OTHER
Intervention: mortality rates
Description: mortality rates
Study: NCT06629012

Intervention type: PROCEDURE
Intervention: Breast reconstruction with neurotization
Description: Patients received breast reconstruction with neurotization procedure

Intervention type: PROCEDURE
Intervention: Breast reconstruction without neurotization
Description: Patients received breast reconstruction without neurotization
Study: NCT06630468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented occupational therapy (TOOT)
Description: The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
Study: NCT04158635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05810857

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor Relearning Program
Description: patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mirror Therapy
Description: Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined
Study: NCT05369416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low sodium diet
Description: Subjects will be started on a low sodium (food will be provided) for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high sodium diet
Description: Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
Study: NCT06504173

Intervention type: PROCEDURE
Intervention: diced cartilage
Description: In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
Study: NCT05820100

Intervention type: OTHER
Intervention: Observational
Description: The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel.

Intervention type: OTHER
Intervention: Observational
Description: The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel.
Study: NCT05288634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
Study: NCT05034484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-303
Description: Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-303
Description: Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered